|
|
发表于 2026-9-20 01:54:06
|
显示全部楼层
mhgo Taking A Close-To-Home Look At The Medicare Billing Data
[quote][size=2][url=forum.php?mod=redirect&goto=findpost&pid=681&ptid=9][color=#999999]ArchieTacle 发表于 2026-6-2 09:42[/color][/url][/size]
Любителям travel-контента и полезных лайфхаков для путе ...[/quote]
Vprr A Top Homelessness Official Ousted From Position Just As Administration Ramps Up Efforts To Tackle Crisis
Despite Costly Failures, Pharma Not Giving Up On Research For Alzheimer MedicationMeanwhile, Stat reports on the future landscape for new diabetes treatments and KHN looks at the lethal drugs used in the aid-in-dying cases.The Wall Street Journal:Alzheimers: Pharmas Great White Whale Is Still Worth HuntingAlzheimers disease is both the largest unmet medical need in the U.S. and the most frustrating challenge for the drug industry. Dont expect pharma companies to get discouraged anytime soon. Last week marked the latest faile [url=https://www.stanleyquencher.uk]stanley cup[/url] d trial of an experimental Alzheimers disease treatment when Merck Co. announced聽results for verubecestat. Eli Lillys solanezumab flunked a clinical trial last November, the third failed late-stage trial for the drug. Grant, 2/20 Stat:Where Are All The New Diabetes Drugs There are few new drugs on the horizon for diabetes, which affects about 29 million Americans. Most of the treatments in late-stage development are simply improved [url=https://www.stanley-ca.ca]stanley website[/url] versions of whats out there 鈥?taken weekly versus daily, or orally instead of by injection. So has pharma run out of ideas in diabetes 聽Not exactly. But whether its ideas will ever get to market is another question. Theres plenty of promising science in the early stages of research. A [url=https://www.hydro-flasks.ca]hydro flask cooler[/url] vailable drugs, however, work pretty well. Given the cost of development and a high bar for approval, pharma can only afford to advance true-blue breakthroughs, and those are hard to come by. Garde, 2/19 Kaiser Health News ocs In N Fhln MedPAC Offers Proposals To Address Unsustainable Drug Costs, But Congressional Action Unlikely
Thursday, Aug 4 2011Lobbyists, Lawmakers Stake Out Positions For Debt Deal Next PhaseAs potential candidates for the super commit [url=https://www.adidas-samba-adidas.fr]adidas samba[/url] tee emerge on Capitol Hill, lobbyists are trying to figure out how to influence the panel s聽decisions and also are gearing up for聽major public relations campaign [url=https://www.owalas.co.nz]owala water bottle[/url] s. Health care interests are likely to be among the most active because they have a great deal at stake. The New York Times: Jockeying Anew In Congress In Next Budget Fight PhaseCongressional leaders have two weeks to name panel members. Names of candidates were circulating Wednesday on Capitol Hill, and some lawmakers have been quietly promoting themselves or their friends for spots on the 12-member panel, which will consist of equal numbers of Republicans and Democrats from the House and the Senate. Lobbyists scrambled Wednesday to figure out how to influence the new panel to protect the programs and tax breaks from which they benefit. Military contractors and health care lobbyists were particularly active, as they have the most to fear Pear, 8/3 . The Washington Post: Debt-Limit Deal Triggers Lobbying Campaign From Health Care And Defense Industries Health care and defense lobbyists are quickly gearing up for [url=https://www.adidas-yeezys.com.mx]yeezy mx[/url] a major lobbying and public relations campaign in response to this week s debt-limit deal, which could force hundreds of billions of dollars in cuts for two of Washington s most powerful industries. The compromise bill that averted a government default th |
|
楼主: root
关注公众号
